Given Epstein‑Barr virus (EBV) serology with negative viral capsid antigen (VCA) immunoglobulin M (IgM), high‑titer VCA immunoglobulin G (IgG), positive EBV nuclear antigen‑1 (EBNA‑1) IgG, and strongly positive early‑antigen D (EA‑D) IgG, what is the appropriate next step in management?

Chronic Active EBV Infection Evaluation

Immediate Next Step

Your serological pattern—negative VCA IgM, very high VCA IgG (>750), positive EBNA-1 IgG (185), and markedly elevated EA-D IgG (>150)—strongly suggests chronic active Epstein-Barr virus infection (CAEBV) and requires immediate quantitative EBV DNA PCR testing of whole blood.

Understanding Your Serological Pattern

Your EBV antibody profile is concerning for CAEBV rather than simple past infection:

• Negative VCA IgM: Rules out acute primary infection 1
• Very high VCA IgG (>750): Exceeds the typical past infection threshold of 1:640, which is characteristic of CAEBV 1
• Markedly elevated EA-D IgG (>150): Substantially exceeds the CAEBV threshold of 1:160, indicating ongoing viral replication 1
• Positive EBNA-1 IgG: Confirms this is not acute infection but rather chronic/reactivated disease 1

This serological pattern—particularly the combination of very high VCA IgG with markedly elevated EA-D IgG—is the hallmark antibody profile described for CAEBV 1.

Required Diagnostic Workup

Essential Testing (Must Be Done)

1. Quantitative EBV DNA PCR on whole blood

• The diagnostic threshold is ≥10,000 IU/mL (or >10^2.5 copies/mg DNA in peripheral blood mononuclear cells) 1, 2
• This is now a required criterion for CAEBV diagnosis 2
• Qualitative PCR is insufficient as healthy individuals can occasionally test positive 1

2. Cell lineage determination of EBV-infected cells

• Must identify whether EBV is infecting T cells, NK cells, or B cells 1, 2
• This requires specialized testing using double-staining techniques, in situ hybridization for EBER, or magnetic bead separation with cell markers 1
• Critical prognostic factor: T-cell infection carries worse prognosis than B-cell infection 1

3. Complete blood count with differential

• Look for thrombocytopenia (poor prognostic indicator) 1
• Assess for large granular lymphocytes or abnormal T/NK cell populations 1

Clinical Assessment Required

Evaluate for persistent or recurrent infectious mononucleosis-like symptoms 1:

• Constitutional: Prolonged/intermittent fever (>3 months), debilitating fatigue 1
• Lymphoproliferative: Lymphadenopathy, hepatosplenomegaly 1
• Organ-specific complications:
  • Hematologic (cytopenias, hemophagocytic lymphohistiocytosis) 1
  • Cardiovascular (coronary aneurysms, valvular disease) 1
  • Dermatologic (hypersensitivity to mosquito bites is characteristic) 1
  • Pulmonary, neurological, gastrointestinal, or ocular manifestations 1

Additional Recommended Testing

If CAEBV is confirmed:

• Immunological studies including HLA-DR expression on lymphocytes 1
• Tissue biopsy of affected organs with EBER in situ hybridization and immunohistochemistry 1
• EBV clonality analysis (Southern blotting) to assess for monoclonal proliferation, which indicates poor prognosis 1
• Chromosomal analysis and T-cell receptor/immunoglobulin rearrangement studies 1

Diagnostic Criteria for CAEBV

All three criteria must be met 1:

1. Persistent or recurrent IM-like symptoms (as detailed above)
2. Unusual EBV antibody pattern with raised VCA IgG (≥1:640) AND raised EA IgG (≥1:160), AND/OR increased EBV genomes in blood/tissues (≥10,000 IU/mL) 1, 2
3. Chronic illness that cannot be explained by other disease processes at diagnosis 1

Critical Pitfalls to Avoid

Do not confuse this with:

• Simple past EBV infection: Would have normal/low EA-D IgG and no symptoms 3
• EBV reactivation in immunocompetent patients: Usually asymptomatic with only mildly elevated EA-D; EBV DNA rarely detectable in blood 4, 5
• Late primary infection: Would typically still have VCA IgM present 5

Important caveat: The presence of all three antibodies (VCA IgG, VCA IgM, EBNA-1 IgG) can occur in both late primary infection and reactivation 5. However, your negative VCA IgM excludes this confusing pattern and points more definitively toward chronic infection 5.

Prognostic Considerations

If CAEBV is confirmed, assess for poor prognostic factors 1:

• Late onset of disease
• Thrombocytopenia
• EBV infection of T cells (versus B cells or NK cells)
• Monoclonal EBV proliferation
• Development of hemophagocytic lymphohistiocytosis or T/NK-cell lymphoma 1

Treatment Implications

If CAEBV is diagnosed:

• Hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment 2
• Chemotherapy may be used to control disease activity prior to HSCT 2
• Close monitoring for development of T-cell or NK-cell lymphoproliferative disorders or lymphomas is essential 1

The majority of patients with severe CAEBV have poor prognosis, with some cases representing a smoldering neoplastic process that can evolve into EBV-associated T-cell lymphomas 1.